{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T10:27:55Z","timestamp":1794911275910,"version":"4.9.1"},"reference-count":96,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2010,11,9]],"date-time":"2010-11-09T00:00:00Z","timestamp":1289260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2010.04268.x","type":"journal-article","created":{"date-parts":[[2010,11,9]],"date-time":"2010-11-09T14:15:12Z","timestamp":1289312112000},"page":"17-25","source":"Crossref","is-referenced-by-count":50,"title":["Monitoring of human papillomavirus vaccination"],"prefix":"10.1093","volume":"163","author":[{"given":"J","family":"Dillner","sequence":"first","affiliation":[{"name":"WHO HPV LabNet Global Reference Laboratory at Department of Clinical Microbiology, University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Arbyn","sequence":"additional","affiliation":[{"name":"Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Unger","sequence":"additional","affiliation":[{"name":"WHO HPV LabNet Global Reference Laboratory at Center for Disease Control, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Dillner","sequence":"additional","affiliation":[{"name":"WHO HPV LabNet Global Reference Laboratory at Department of Clinical Microbiology, University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,11,9]]},"reference":[{"key":"2021122708481749900_b1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/infdis\/174.5.927","article-title":"The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women","volume":"174","author":"Carter","year":"1996","journal-title":"J Infect Dis"},{"key":"2021122708481749900_b2","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"key":"2021122708481749900_b3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1055-9965.EPI-03-0191","article-title":"Natural history of human papillomavirus type 16 virus-like particle antibodies in young women","volume":"13","author":"Ho","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122708481749900_b4","first-page":"233","article-title":"Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix","volume":"6","author":"Shah","year":"1997","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122708481749900_b5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1386-6532(01)00172-X","article-title":"Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction","volume":"22","author":"Lehtinen","year":"2001","journal-title":"J Clin Virol"},{"key":"2021122708481749900_b6","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/infdis\/173.6.1394","article-title":"Seropositivity to human papillomavirus types 16, 18 or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour","volume":"173","author":"Dillner","year":"1996","journal-title":"J Infect Dis"},{"key":"2021122708481749900_b7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/89.17.1293","article-title":"Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer","volume":"89","author":"Dillner","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"2021122708481749900_b8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/scbi.1999.0146","article-title":"The serological response to papillomaviruses","volume":"9","author":"Dillner","year":"1999","journal-title":"Semin Cancer Biol"},{"key":"2021122708481749900_b9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0738-081X(85)90047-1","article-title":"Human papillomaviruses. Biochemical and biologic properties","volume":"3","author":"Orth","year":"1985","journal-title":"Clin Dermatol"},{"key":"2021122708481749900_b10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/gyno.1994.1239","article-title":"Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination","volume":"55","author":"Hines","year":"1994","journal-title":"Gynecol Oncol"},{"key":"2021122708481749900_b11","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1128\/jvi.70.5.3298-3301.1996","article-title":"Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition","volume":"70","author":"Roden","year":"1996","journal-title":"J Virol"},{"key":"2021122708481749900_b12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0042-6822(91)90890-N","article-title":"The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes","volume":"181","author":"Christensen","year":"1991","journal-title":"Virology"},{"key":"2021122708481749900_b13","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/JVI.73.7.6188-6190.1999","article-title":"Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6","volume":"73","author":"Kawana","year":"1999","journal-title":"J Virol"},{"key":"2021122708481749900_b14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/viro.2000.0272","article-title":"Minor capsid protein of human genital papillomaviruses contains subdominant, crossneutralizing epitopes","volume":"270","author":"Roden","year":"2000","journal-title":"Virology"},{"key":"2021122708481749900_b15","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1128\/JVI.73.6.4882-4889.1999","article-title":"Characterization of a major neutralizing epitope on human papillomavirus type 16 L1","volume":"73","author":"White","year":"1999","journal-title":"J Virol"},{"key":"2021122708481749900_b16","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1073\/pnas.95.4.1800","article-title":"Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model","volume":"95","author":"Greenstone","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122708481749900_b17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1097-4644(19990501)73:2<145::AID-JCB1>3.0.CO;2-5","article-title":"Chimeric papillomavirus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response","volume":"73","author":"Nieland","year":"1999","journal-title":"J Cell Biochem"},{"key":"2021122708481749900_b18","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djp106","article-title":"Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines","volume":"101","author":"Jagu","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2021122708481749900_b19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","article-title":"Expression of vaccinia recombinant HPV156 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"key":"2021122708481749900_b20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/jnci\/86.7.494","article-title":"A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16","volume":"86","author":"Kirnbauer","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"2021122708481749900_b21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399498000210","article-title":"Human cellular immune responses against human papillomaviruses in cervical neoplasia","volume":"1998","author":"Man","year":"1998","journal-title":"Exp Rev Mol Med"},{"key":"2021122708481749900_b22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tim.2003.12.011","article-title":"Dendritic cells: the host Achille's heel for mucosal pathogens?","volume":"12","author":"Niedergang","year":"2004","journal-title":"Trends Microbiol"},{"key":"2021122708481749900_b23","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/13543784.13.8.959","article-title":"Recent developments in human papillomavirus vaccines","volume":"13","author":"Stern","year":"2004","journal-title":"Exp Opin Investig Drugs"},{"key":"2021122708481749900_b24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","article-title":"Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine","volume":"93","author":"Harro","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"2021122708481749900_b25","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1086\/323645","article-title":"Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer","volume":"184","author":"Brown","year":"2001","journal-title":"J Infect Dis"},{"key":"2021122708481749900_b26","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1016\/j.vaccine.2004.02.020","article-title":"A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine","volume":"22","author":"Ault","year":"2004","journal-title":"Vaccine"},{"key":"2021122708481749900_b27","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1086\/320190","article-title":"A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers","volume":"183","author":"Evans","year":"2001","journal-title":"J Infect Dis"},{"key":"2021122708481749900_b28","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122708481749900_b29","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"2021122708481749900_b30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prohylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"2021122708481749900_b31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus 16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"key":"2021122708481749900_b32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4\u20135 years of bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"2021122708481749900_b33","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical intraepithelial neoplasia","volume":"356","author":"Females United to Unilaterally Reduce Endo\/Ectocervical Disease (FUTURE II) Study Group","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122708481749900_b34","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122708481749900_b35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"2021122708481749900_b36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"2021122708481749900_b37","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ygyno.2008.06.027","article-title":"A review of cross-protection against oncogenic HPV by an HPV-16\/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention","volume":"110","author":"Jenkins","year":"2008","journal-title":"Gynecol Oncol"},{"key":"2021122708481749900_b38","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"key":"2021122708481749900_b39","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"2021122708481749900_b40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"Zur Hausen","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2021122708481749900_b41","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jcv.2004.11.019","article-title":"HPV-mediated transformation of the anogenital tract","volume":"32","author":"Steenbergen","year":"2005","journal-title":"J Clin Virol"},{"issue":"1","key":"2021122708481749900_b42","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jcv.2004.12.005","article-title":"Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination","volume":"32","author":"Stern","year":"2005","journal-title":"J Clin Virol"},{"key":"2021122708481749900_b43","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(09)70227-X","article-title":"Development of therapeutic HPV vaccines","volume":"10","author":"Trimble","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122708481749900_b44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14712598.8.4.421","article-title":"Therapeutic human papillomavirus vaccines: current clinical trials and future directions","volume":"8","author":"Hung","year":"2008","journal-title":"Exp Opin Biol Ther"},{"key":"2021122708481749900_b45","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/14760584.2.3.381","article-title":"Progress in prophylactic and therapeutic vaccines for human papillomavirus infection","volume":"2","author":"Stanley","year":"2003","journal-title":"Exp Rev Vaccines"},{"key":"2021122708481749900_b46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.vaccine.2006.05.123","article-title":"Chapter 17: second generation HPV vaccines to prevent cervical cancer","volume":"24","author":"Schiller","year":"2006","journal-title":"Vaccine"},{"key":"2021122708481749900_b47","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1016\/j.vaccine.2008.08.067","article-title":"Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006\u2013January 2008","volume":"26","author":"Koulova","year":"2008","journal-title":"Vaccine"},{"key":"2021122708481749900_b48","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.ejca.2009.07.023","article-title":"The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey","volume":"45","author":"L\u00e9vy-Bruhl","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122708481749900_b49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.vaccine.2006.06.015","article-title":"Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease","volume":"24","author":"Lacey","year":"2006","journal-title":"Vaccine"},{"key":"2021122708481749900_b50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1470-2045(05)70086-3","article-title":"Carcinogenicity of human papillomaviruses","volume":"6","author":"Cogliano","year":"2005","journal-title":"Lancet Oncol"},{"key":"2021122708481749900_b51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.vaccine.2004.07.046","article-title":"Efficacy and other milestones for human papillomavirus vaccine introduction","volume":"23","author":"Pagliusi","year":"2004","journal-title":"Vaccine"},{"key":"2021122708481749900_b52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/oxfordjournals.jncimonographs.a003472","article-title":"Chapter 16: prophylactic human papillomavirus vaccines","volume":"31","author":"Lowy","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2021122708481749900_b53","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"2021122708481749900_b54","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ygyno.2008.06.029","article-title":"Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16\/18 infection and cervical disease in women 15\u201325 years of age","volume":"110","author":"Harper","year":"2008","journal-title":"Gynecol Oncol"},{"key":"2021122708481749900_b55","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1016\/j.vaccine.2008.09.073","article-title":"HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine","volume":"26","author":"Joura","year":"2008","journal-title":"Vaccine"},{"key":"2021122708481749900_b56","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199210293271804","article-title":"A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection","volume":"327","author":"Koutsky","year":"1992","journal-title":"N Engl J Med"},{"key":"2021122708481749900_b57","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(00)04956-4","article-title":"Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study","volume":"357","author":"Woodman","year":"2001","journal-title":"Lancet"},{"key":"2021122708481749900_b58","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/aje\/kwf180","article-title":"Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students","volume":"157","author":"Winer","year":"2003","journal-title":"J Epidemiol"},{"key":"2021122708481749900_b59","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.bjc.6603575","article-title":"Strategies for the introduction of HPV vaccination: modelling the optimum age and sex specific pattern of vaccination in Finland","volume":"96","author":"French","year":"2007","journal-title":"Br J Cancer"},{"key":"2021122708481749900_b60","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1016\/j.vaccine.2008.07.041","article-title":"Seroepidemiology as basis for design of a human papillomavirus vaccination program","volume":"26","author":"Ryding","year":"2008","journal-title":"Vaccine"},{"key":"2021122708481749900_b61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcv.2006.12.009","article-title":"Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in cervical cancer screening","volume":"38","author":"Arbyn","year":"2007","journal-title":"J Clin Virol"},{"key":"2021122708481749900_b62","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2005.09.011","article-title":"Impact of HPV infection in adolescent populations","volume":"37","author":"Moscicki","year":"2005","journal-title":"J Adolesc Health"},{"key":"2021122708481749900_b63","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.5858\/133.8.1276","article-title":"Statement of human papillomavirus DNA test utilization","volume":"133","author":"Solomon","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"2021122708481749900_b64","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001648-200211000-00006","article-title":"The theoretical population-level impact of a prophylactic human papilloma virus vaccine","volume":"13","author":"Hughes","year":"2002","journal-title":"Epidemiology"},{"key":"2021122708481749900_b65","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"2021122708481749900_b66","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1086\/425271","article-title":"Role of herd immunity in determining the effect of vaccines against sexually transmitted disease","volume":"19","author":"Garnett","year":"2005","journal-title":"J Infect Dis"},{"key":"2021122708481749900_b67","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vaccine.2006.05.116","article-title":"Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes","volume":"24","author":"Garnett","year":"2006","journal-title":"Vaccine"},{"key":"2021122708481749900_b68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.0030138","article-title":"Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses","volume":"3","author":"Barnabas","year":"2006","journal-title":"PLoS Med"},{"key":"2021122708481749900_b69","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(04)17410-2","article-title":"Vaccination against human papillomaviruses shows great promise","volume":"364","author":"Lehtinen","year":"2004","journal-title":"Lancet"},{"key":"2021122708481749900_b70","first-page":"1","article-title":"Preparations for implementing human papillomavirus vaccination should begin","volume":"10","author":"Lehtinen","year":"2005","journal-title":"Euro Surveill"},{"key":"2021122708481749900_b71","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1258\/095646206778145550","article-title":"Enrolment of 22\u2003000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing","volume":"17","author":"Lehtinen","year":"2006","journal-title":"Int J STD AIDS"},{"key":"2021122708481749900_b72","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1258\/095646206776253453","article-title":"Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy","volume":"17","author":"Lehtinen","year":"2006","journal-title":"Int J STD AIDS"},{"key":"2021122708481749900_b73","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","author":"Schiller","year":"2009","journal-title":"J Infect Dis"},{"key":"2021122708481749900_b74","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122708481749900_b75","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int J Cancer"},{"key":"2021122708481749900_b76","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/annonc\/mdm079","article-title":"Burden of cervical cancer in Europe: estimates for 2004","volume":"18","author":"Arbyn","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122708481749900_b77","first-page":"1425","article-title":"Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004","volume":"18","author":"Arbyn","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122708481749900_b78","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1073\/pnas.94.12.6571","article-title":"Vaccination against colonizing bacteria with multiple serotypes","volume":"94","author":"Lipsitch","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122708481749900_b79","first-page":"953","article-title":"Correlates of the spread of human papillomavirus infection","volume":"9","author":"Silins","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122708481749900_b80","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00007435-200307000-00010","article-title":"Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities","volume":"30","author":"Rousseau","year":"2003","journal-title":"Sex Transm Infect"},{"key":"2021122708481749900_b81","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1086\/444391","article-title":"Instituto Nacional de Cancerologia Human Papillomavirus Study Group. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines","volume":"192","author":"Mendez","year":"2005","journal-title":"J Infect Dis"},{"key":"2021122708481749900_b82","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ijc.20970","article-title":"Chlamydia trachomatis infection and persistence of human papillomavirus","volume":"116","author":"Silins","year":"2005","journal-title":"Int J Cancer"},{"key":"2021122708481749900_b83","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/viro.2000.0702","article-title":"NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16","volume":"279","author":"Pastrana","year":"2001","journal-title":"Virology"},{"key":"2021122708481749900_b84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1158\/1055-9965.EPI-08-0510","article-title":"Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium","volume":"18","author":"Arbyn","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122708481749900_b85","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bjc.6603843","article-title":"HPV type-specific risks of high grade CIN during 4 years of follow-up: a population-based prospective study","volume":"97","author":"Naucl\u00e9r","year":"2007","journal-title":"Br J Cancer"},{"key":"2021122708481749900_b86","doi-asserted-by":"crossref","first-page":"pii: 19119","DOI":"10.2807\/ese.14.06.19119-en","article-title":"Introduction of human papillomavirus (HPV) vaccination in Sweden","volume":"14","author":"Tegnell","year":"2009","journal-title":"Euro Surveill"},{"key":"2021122708481749900_b87","doi-asserted-by":"crossref","DOI":"10.1159\/000314010","article-title":"Introduction of HPV vaccination in Belgium, Luxembourg and the Netherlands","author":"Arbyn","year":"2010","journal-title":"Gynecol Obstet Invest"},{"key":"2021122708481749900_b88","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex Transm Infect"},{"key":"2021122708481749900_b89","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.ejca.2009.07.019","article-title":"HPV infection in Europe","volume":"45","author":"De Vuyst","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"2021122708481749900_b90","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"Chapter 2: the burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"key":"2021122708481749900_b91","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1016\/j.ejca.2009.07.024","article-title":"What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination","volume":"45","author":"Lynge","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122708481749900_b92","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2021122708481749900_b93","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrmicro867","article-title":"Delivering on the promise: HPV vaccines and cervical cancer","volume":"2","author":"Schiller","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"2021122708481749900_b94","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.ejca.2009.07.016","article-title":"The challenges for organising cervical screening programmes in the 15 old member states of the European Union","volume":"45","author":"Arbyn","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122708481749900_b95","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/ijc.21515","article-title":"Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses","volume":"118","author":"Ferguson","year":"2006","journal-title":"Int J Cancer"},{"key":"2021122708481749900_b96","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1128\/JCM.44.2.571-579.2006","article-title":"Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA","volume":"44","author":"Quint","year":"2006","journal-title":"J Clin Microbiol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2010.04268.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/163\/1\/17\/41924223\/j.1365-2249.2010.04268.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/163\/1\/17\/41924223\/j.1365-2249.2010.04268.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:23:12Z","timestamp":1641054192000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/163\/1\/17\/6438714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,9]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,11,9]]},"published-print":{"date-parts":[[2010,12,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04268.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,1]]},"published":{"date-parts":[[2010,11,9]]}}}